Our team consists of executives with backgrounds in the pharmaceutical industry and investment banking. Their combined experience links drug development with corporate and financial strategy.
Drug Development Professional
Seasoned pharma/biotech professional with extensive background in drug development and technical operations. Pioneered biosimilars, vaccines, gene therapies, and orphan drugs. Skilled in selling and acquiring highly complex technologies and products, including those relevant for the CDMO industry. Adept at attracting customers, in- and out-licensing, due diligence, fundraising, and investing. Advisor to a Venture Capital Fund, a Family Office and a Boutique Investment Bank. Managed large capital investment programs from planning to new site commissioning. PhD in Organic Chemistry.
Project Integrator of BioNTech’s project Lightspeed, the world’s fastest development ever of a preventive vaccine, saving millions of lives, preventing millions of hospitalizations. Major contributor to five products reaching market across diverse therapeutic areas. Expertise in biopharmaceutical R&D strategy, interdisciplinary team leadership, and program/portfolio management & execution. Background combines scientific and commercial insights with program execution from preclinical to launch. PhD in Organic Chemistry. Advises on how to convert a good plan into even better project execution. Committed to initiatives bringing new treatments to patients and preventive vaccines to people in need – as quickly as possible.
Former Vice President in Investment Banking with a specialized focus on Healthcare, Medical Technology, and Diagnostics. Extensive expertise in originating and executing strategic and financial transactions across both private and public markets. Successfully conducted over 20 due diligence processes, including transactions with values ranging from $50 million to $4 billion. Earned his Bachelor of Science (B.S.) in Management, with a concentration in Finance, from Boston College in 2019. Bryan became one of the youngest professionals to achieve the prestigious Vice President designation in the industry.
Jake spearheads the healthcare and life sciences advisory practice of Echo Partners, a firm specializing in solving to navigate complex transactions and deliver exceptional client outcomes. Before Echo Partners, Jake founded Inflow – partnering with 50+ middle-market banks, including Madison Street Capital, Auctus Capital Partners and DelMorgan & Co., to design business-development programs and originate healthcare-focused transactions. His deep network across biotech, diagnostics and med-tech enables him to provide precise M&A and capital-raise solutions.
